Market Overview

Moleculin Investors Rewarded As Annamycin Trial Advances To Next Cohort

Moleculin Investors Rewarded As Annamycin Trial Advances To Next Cohort

Moleculin Biotech Inc (NASDAQ: MBRX) announced positive data Thursday from its Phase 1/2 study of annamycin in Poland.

Annamycin is an anthracycline antibiotic being investigated for the treatment of cancer. The company said intends to advance the clinical study of Annamycin to the next dose level.

“We remain optimistic that new methods for reducing the onset of mucositis (the dose limiting toxicity for Annamycin in prior clinical trials) will allow us to safely increase dosing to 180 mg/m2 or potentially even higher,” CEO Walter Klemp said in a statement.

One of the drug's advantages is a lack of cardiotoxicity, he said. 

"We continue to see no evidence of cardiotoxicity in any of the patients treated thus far. We intend to advance the clinical study of Annamycin with the goal of ultimately demonstrating the drug's safety and effectiveness to support regulatory approval in both the U.S. and European Union." 

Moleculin Biotech shares were trading higher by 1.63% to $1.25 at the time of publication Thursday. 

Related Links:

Cancer Genetics Sharply Higher After Interpace Buys Biopharma Unit

14 Stocks To Watch For July 18, 2019

Posted-In: AnnamycinBiotech News General Best of Benzinga


Related Articles (MBRX)

View Comments and Join the Discussion!
Fastest Market News Application
You'll Hear It First On Pro
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

Netflix Short Sellers Up $800M On Subscriber Miss

Worries Over Progress On Trade, Earnings Uncertainty Cloud Market Sentiment